Clinical features and outcomes of ALK rearranged non ‐small cell lung cancer with primary resistance to crizotinib

ConclusionPatients with primary resistance to crizotinib displayed unfavorable survival outcomes and the underlying mechanism cannot be identified in clinical features. Nevertheless, next ‐generation ALK inhibitors and chemotherapy after crizotinib progression could confer a therapeutic and survival benefit in this population.

Source: Thoracic Cancer - April 15, 2019 Category: Cancer & Oncology Authors: Di Ma, Yan Zhang, Puyuan Xing, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Hongge Liang, Yang Du, Zhaohui Zhang, Li Liang, Junling Li Tags: ORIGINAL ARTICLE Source Type: research